3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Plasma cell
2
Lymphoid
2
Thoracic
1
Other hematologic neoplasm
1
Myeloid
1
Genitourinary
1
Gastrointestinal
1
Classical hematology
1
Breast
1
Conditions
Venous Thrombosis
1
Venous Thromboembolism
1
Vascular Diseases
1
Urogenital Neoplasms
1
Thromboembolism
1
Prostatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Lung Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Digestive System Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
8
pembrolizumab
6
Filgrastim
5
Busulfan
5
fludarabine phosphate
4
fludarabine
4
Nivolumab
4
Flow Cytometry
4
Antilymphocyte Serum
4
Alemtuzumab
4
Tacrolimus
3
Stem Cell Transplantation
3
Sirolimus
3
Radiotherapy
3
Peripheral Blood Stem Cell Transplantation
3
Paclitaxel
3
Mycophenolic Acid
3
Melphalan
3
Dexamethasone
3
Carboplatin
3
Biopsy
3
Azacitidine
3
valspodar
2
atezolizumab
2
aldesleukin
2
X-Rays
2
Vorinostat
2
Vincristine
2
Thiotepa
2
Psychiatric Rehabilitation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma
×
Tinzaparin
×
Genitourinary
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled